Drug Costs – Talk Bio

FDA Unveils Long-Awaited Biosimilar Guidance to Accelerate Approvals and Cut Costs

1 month ago talkbio0Tagged Biopharmaceuticals, biosimilar guidance, biosimilarity, Clinical Research, Comparative Efficacy, draft guidance, Drug Costs, four-letter suffix, naming convention, United States Food and Drug Administration

FDA; biosimilar guidance; 2025 draft guidance; comparative efficacy study; analytical assessment; four-letter suffix; naming convention; biosimilarity; drug costs; biologic medicines

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

7 months ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs

Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices

1 year ago talkbio0Tagged Benefit, Co-Manufacturing, competition, Drug Costs, Evaluation, Healthcare Industry, manager, Pharmaceutical Services, Pharmacy Benefit Manager, United States Federal Trade Commission

PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry